KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Non-Current Deffered Revenue: 2017-2025

Historic Non-Current Deffered Revenue for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $157.0 million.

  • Moderna's Non-Current Deffered Revenue rose 65.26% to $157.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.0 million, marking a year-over-year increase of 65.26%. This contributed to the annual value of $58.0 million for FY2024, which is 30.12% down from last year.
  • Latest data reveals that Moderna reported Non-Current Deffered Revenue of $157.0 million as of Q3 2025, which was up 141.54% from $65.0 million recorded in Q2 2025.
  • Moderna's Non-Current Deffered Revenue's 5-year high stood at $692.0 million during Q2 2023, with a 5-year trough of $58.0 million in Q1 2024.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $95.0 million (2024), whereas its average is $200.0 million.
  • As far as peak fluctuations go, Moderna's Non-Current Deffered Revenue soared by 247.46% in 2021, and later tumbled by 91.38% in 2024.
  • Quarterly analysis of 5 years shows Moderna's Non-Current Deffered Revenue stood at $615.0 million in 2021, then rose by 9.43% to $673.0 million in 2022, then plummeted by 87.67% to $83.0 million in 2023, then plummeted by 30.12% to $58.0 million in 2024, then spiked by 65.26% to $157.0 million in 2025.
  • Its Non-Current Deffered Revenue stands at $157.0 million for Q3 2025, versus $65.0 million for Q2 2025 and $58.0 million for Q1 2025.